State Street SPDR S&P Biotech ETF (XBI)
| Assets | $7.91B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 62.48M |
| Dividend (ttm) | $0.44 |
| Dividend Yield | 0.33% |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 6,468,357 |
| Open | 132.49 |
| Previous Close | 132.78 |
| Day's Range | 131.47 - 134.29 |
| 52-Week Low | 78.00 |
| 52-Week High | 139.19 |
| Beta | 0.85 |
| Holdings | 153 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
15.27% of assets| Name | Symbol | Weight |
|---|---|---|
| Revolution Medicines, Inc. | RVMD | 1.76% |
| Travere Therapeutics, Inc. | TVTX | 1.72% |
| TG Therapeutics, Inc. | TGTX | 1.65% |
| Alkermes plc | ALKS | 1.55% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1.55% |
| Cytokinetics, Incorporated | CYTK | 1.44% |
| Celcuity Inc. | CELC | 1.41% |
| Exelixis, Inc. | EXEL | 1.40% |
| Neurocrine Biosciences, Inc. | NBIX | 1.39% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 1.39% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.40656 | Dec 24, 2025 |
| Sep 22, 2025 | $0.02665 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
| Sep 23, 2024 | $0.01523 | Sep 25, 2024 |
Performance
XBI had a total return of 66.58% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.08%.
News
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
The biotech sector took a hit this week despite a recent spike in search activity. The SPDR S&P Biotech ETF ($XBI) and iShares Biotechnology ETF ($IBB) declined slightly, while two…
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
The SPDR S&P Biotech ETF ($XBI) is drawing fresh investor attention as analysts maintain a bullish outlook on some of its underlying holdings. The fund, which tracks an equal-weighted index…
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
Why 2026 may be a strong year for biotech stocks
Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid-cap biotech names – posting one of its strongest stretches on record. Mizu...
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Final Trades: Toast, Uber, the XLB and the XBI
The Investment Committee reveals the stocks they're watching as the market sets up for its next move.
The Fed cut rates. Biotech didn't notice.
Biotechs are instead spending their time advancing the kind of smart science that will catch the eye of cash-rich pharmaceutical companies.
Final Trades: FTAI, ETN, COWZ, XBI
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Taiwan Semi, Apple and the XBI
The Investment Committee give you their top stocks to watch for the second half.
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Trade Tracker: Joe Terranova buys more XBI
Joe Terranova, senior managing director at Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying XBI again. The committee share their health care strategy.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
Final Trades: SoFi Technologies, Clearway Energy, SPDR S&P Biotech ETF and CrowdStrike
The Investment Committee's top stock picks are in—here's what they're watching now.
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Unusually active option classes on open September 2nd
Unusual total active option classes on open include: MannKind (MNKD), Zscaler (ZS), Kroger (KR), First Majestic Silver (AG), JetBlue (JBLU), SPDR S&P Biotech (XBI), Direxion Daily 20 plus Year Treasur...
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Home builders lose confidence, resort to price cuts as buyers steer clear of housing market
Builders' confidence in the housing market sank in June, the National Association of Home Builders said.
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Political pressure and persistently high interest rates have some wondering if the industry's model is broken.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Single stock picking is the only way to make money in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Trade Tracker: Joe Terranova buys the XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss why he's buying the Biotech ETF.
Final Trade: LNG, XLP, X, XBI
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...
Is Biotech's Bull Run Over? Examining Election Impacts
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on No...
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
Unusually active option classes on open November 6th
Unusual total active option classes on open include: Global Payments (GPN), SPDR S&P Retail (XRT), Astera Labs Inc (ALAB), SPDR S&P Biotech (XBI), CVS Health (CVS), Halliburton (HAL), Direxion Daily…
Unusually active option classes on open October 1st
Unusual total active option classes on open include: iShares MSCI China (MCHI), Applied Therapeutics (APLT), Carrier Global (CARR), SPDR S&P Biotech (XBI), iShares DJ US Real Estate Index Fund (IYR),…
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begi...